Product Description: Zoldonrasib (RMC-9805) is a potent and orally active KRAS G12D inhibitor.Zoldonrasib induces apoptosis in KRAS G12D mutant cancer cells. Zoldonrasib has the potential for the research of KRAS G12D mutant cancer[1][2].
Formula: C63H88F3N11O7
References: [1]BLAKE JAMES F, et al. Preparation of peptide-linked macrocyclic dipeptides as Ras inhibitors.World Intellectual Property Organization, WO2023060253 A1 2023-04-13/[2]Knox, J et al.RMC-9805, a first-in-class, mutant-selective, covalent and orally bioavailable KRASG12D(ON) inhibitor, promotes cancer-associated neoantigen recognition and synergizes with immunotherapy in preclinical models. Cancer Res 1 April 2023; 83 (7_Supplement): 3475/[3]John E. Knox, et al. Discovery of RMC-9805, an Oral, RAS(ON) G12D-Selective Covalent Tri-Complex Inhibitor.
CAS Number: 2922732-54-3
Molecular Weight: 1168.44
Compound Purity: 99.73
Research Area: Cancer
Solubility: DMSO : 100 mg/mL (ultrasonic)
Target: Apoptosis;Ras
English
Deutsch
